Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Grenoble – page 48

663 clinical trials in Grenoble, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Grenoble at a glance
663
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

663 trials in Grenoble

Open in trial search

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Not recruiting

Study on Livmoniplimab and Budigalimab with Chemotherapy for Adults with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Focal segmental glomerulosclerosis+1

Not recruiting

Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:R3R01
  • Sponsor:River 3 Renal Corp.

Clostridium difficile infection

Not recruiting

Study on Preventing C. difficile Infections with Oral Vancomycin in Patients Undergoing Allogeneic Stem Cell Transplantation

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vancomycin
  • Sponsor:Assistance Publique Hopitaux De Paris

Hypertension

Not recruiting

Study on the Effectiveness of Ethanol in Treating Hypertension in Patients with Uncontrolled High Blood Pressure

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ethanol, Anhydrous
  • Sponsor:Ablative Solutions Inc.

Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluconazole
  • Sponsor:Mundipharma Research Limited

Sickle cell disease

Not recruiting

Study on the Effectiveness of Decitabine and Tetrahydrouridine in Patients with Sickle Cell Disease Not Eligible for Hydroxyurea Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Novo Nordisk A/S

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Neoplasm

Not recruiting

Study on the Safety and Effects of [177Lu]-NeoB in Patients with Advanced Solid Tumors Overexpressing GRPR

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU)-NEOBOMB1
  • Sponsor:Advanced Accelerator Applications International S.A.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Grenoble

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck cancers, multiple myeloma, and various types of leukemia. Studies evaluate novel combination therapies and targeted treatments for improved patient outcomes.

  • Advanced NSCLC Treatment Studies
  • Gastric Cancer Immunotherapy
  • Hematologic Malignancies

Innovative approaches combining immunotherapy with standard treatments are showing promise in treating various forms of cancer.

02 Transplant Medicine

Clinical investigations examining kidney transplant outcomes and rejection prevention. Research focuses on new therapeutic approaches for managing transplant-related complications.

  • Antibody-Mediated Rejection
  • Novel Immunosuppression Strategies
  • Long-term Graft Survival

Studies aim to improve transplant success rates and reduce rejection incidents through innovative medication protocols.

03 Neurological Disorders

Research into narcolepsy and multiple sclerosis treatments, evaluating new therapeutic approaches for better symptom management and disease control.

  • Sleep Disorder Management
  • MS Treatment Innovations
  • Neurological Disease Progression

Cutting-edge treatments being developed to address both rare and common neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.